Vasoactive intestinal polypeptide level in gastroesophageal reflux disease before and after surgical treatment
DOI:
https://doi.org/10.14739/2310-1210.2023.4.278576Keywords:
gastroesophageal reflux disease, vasoactive intestinal peptide, gastroesophageal reflux disease, vasoactive intestinal peptideAbstract
From year to year, wide spread of gastroesophageal reflux disease (GERD) is attracting greater attention of specialists in the field of this pathology diagnosis and treatment. In-depth studies on etiological and pathogenetic factors in the GERD development are being conducted. Of particular interest is the role of humoral factors, one of which is vasoactive intestinal peptide (VIP). There are currently no data on the dynamics of this hormone during surgical treatment of GERD.
The aim of the study was to examine the dynamics of plasma VIP during surgical treatment of GERD and its influence on the lower esophageal sphincter (LES) function.
Materials and methods. Surgical treatment in the Nissen modification was performed for 35 patients with GERD. There were 26 women (74.3 %), men – 9 (25.7 %). mean age – 55.3 ± 11.3 years. Comparison group – 20 apparently healthy individuals: women – 14 (70.0 %); men – 6 (30.0 %), mean age – 56.7 ± 10.6 years. VIP was measured in venous blood plasma by an enzyme immunoassay (Vasoactive intestinal peptide ELISA, S-1201, BCM Diagnostics) using an immunoenzyme complex ImmunoChem-2100 (USA). The sampling of the studied samples in the main group was carried out before the operation and 2–3 months post-surgery.
Results. In the main group before the surgery, the level of VIP was 3.1 ± 1.1 ng/ml, after the surgery – 2.2 ± 1.0 ng/ml. In the comparison group, VIP was determined at the level of 2.1 ± 1.1 ng/ml. In GERD before the surgery, the VIP level was statistically different from the indicators in the comparison group and from postoperative values. After surgical treatment, VIP values were decreased to the level of apparently healthy individuals. There was a positive correlation between the VIP level and acid exposure time (AET), the total number of refluxes, the number of reflux events longer than 5 minutes, the maximum duration of refluxes and the degree of esophageal inflammation.
Conclusions. In the surgical treatment of GERD, the statistically significant decrease in the VIP level to that of apparently healthy individuals is determined. The moderate positive correlation between the levels of VIP, AET, the average number of refluxes, the number of reflux events longer than 5 minutes, and the maximum duration of refluxes confirms the inhibitory effect of VIP on LES tone. The relationship between the degree of esophageal inflammation and the VIP level confirms the indirect, through the action of VIP, inhibitory effect of the esophagitis severity on the LES tone.
References
Sandhu, D. S., & Fass, R. (2018). Current Trends in the Management of Gastroesophageal Reflux Disease. Gut and liver, 12(1), 7-16. https://doi.org/10.5009/gnl16615
Katzka, D. A., & Kahrilas, P. J. (2020). Advances in the diagnosis and management of gastroesophageal reflux disease. BMJ (Clinical research ed.), 371, m3786. https://doi.org/10.1136/bmj.m3786
Slater, B. J., Dirks, R. C., McKinley, S. K., Ansari, M. T., Kohn, G. P., Thosani, N., Qumseya, B., Billmeier, S., Daly, S., Crawford, C., P Ehlers, A., Hollands, C., Palazzo, F., Rodriguez, N., Train, A., Wassenaar, E., Walsh, D., Pryor, A. D., & Stefanidis, D. (2021). SAGES guidelines for the surgical treatment of gastroesophageal reflux (GERD). Surgical endoscopy, 35(9), 4903-4917. https://doi.org/10.1007/s00464-021-08625-5
Richter, J. E., & Rubenstein, J. H. (2018). Presentation and Epidemiology of Gastroesophageal Reflux Disease. Gastroenterology, 154(2), 267-276. https://doi.org/10.1053/j.gastro.2017.07.045
Horgan, S., & Fuchs, K.-H. (2020). Management of Gastroesophageal Reflux Disease. Surgical and Therapeutic Innovations. Springer Nature Switzerland AG. http://doi.org/10.1007/978-3-030-48009-7
Yadlapati, R., Gyawali, C. P., Pandolfino, J. E., & CGIT GERD Consensus Conference Participants (2022). AGA Clinical Practice Update on the Personalized Approach to the Evaluation and Management of GERD: Expert Review. Clinical gastroenterology and hepatology, 20(5), 984-994.e1. https://doi.org/10.1016/j.cgh.2022.01.025
Chen, S., Du, F., Zhong, C., Liu, C., Wang, X., Chen, Y., Wang, G., Gao, X., Zhang, L., Li, L., & Wu, W. (2021). Gastroesophageal reflux disease: recent innovations in endoscopic assessment and treatment. Gastroenterology report, 9(5), 383-391. https://doi.org/10.1093/gastro/goab029
Schoppmann, S. F., & Riegler, M. (Eds.). (2021). Multidisciplinary Management of Gastroesophageal Reflux Disease. Springer, Cham. https://doi.org/10.1007/978-3-030-53751-7
Fuchs, K. H., & Meining, A. (2021). Current Insights in the Pathophysiology of Gastroesophageal Reflux Disease. Chirurgia (Bucharest, Romania : 1990), 116(5), 515-523. https://doi.org/10.21614/chirurgia.116.5.515
Fuchs, K. H., Lee, A. M., Breithaupt, W., Varga, G., Babic, B., & Horgan, S. (2021). Pathophysiology of gastroesophageal reflux disease-which factors are important?. Translational gastroenterology and hepatology, 6, 53. https://doi.org/10.21037/tgh.2020.02.12
Chen, J., & Brady, P. (2019). Gastroesophageal Reflux Disease: Pathophysiology, Diagnosis, and Treatment. Gastroenterology nursing, 42(1), 20-28. https://doi.org/10.1097/SGA.0000000000000359
Singhartinger, F. X., Wahl, L., Weitzendorfer, M., Gantschnigg, A., Koch, O. O., & Emmanuel, K. (2022). The role of hormones in symptoms and pathophysiology of reflux and esophageal motility disorders. Die Rolle von Hormonen bei Symptomen und Pathophysiologie von Reflux und Ösophagusmotilitätsstörungen. Zeitschrift fur Gastroenterologie, 10.1055/a-1833-9494. Advance online publication. https://doi.org/10.1055/a-1833-9494
Sadatomi, D., Kono, T., Mogami, S., & Fujitsuka, N. (2020). Weak acids induce PGE2 production in human oesophageal cells: novel mechanisms underlying GERD symptoms. Scientific reports, 10(1), 20775. https://doi.org/10.1038/s41598-020-77495-z
Giuli, R., Siewert, J. R., Couturier, D., & Scarpignato. C. (Eds.). (2003). Barrett’s esophageus (vol. 1). John Libbey Eurotext.
Pouderoux, P., Verdier, E., & Kahrilas, P. J. (2003). Patterns of esophageal inhibition during swallowing, pharyngeal stimulation, and transient LES relaxation. Lower esophageal sphincter. American journal of physiology. Gastrointestinal and liver physiology, 284(2), G242-G247. https://doi.org/10.1152/ajpgi.00301.2002)
Fuchs, K. H., Babic, B., & Fuchs, H. F. (2019). Esophageal Sphincters in Health and Disease. In C. J. Yeo, S. R. DeMeester, & D. W. McFadden (Eds.), Shackelford's Surgery of the Alimentary (8th ed., Vol. 2, pp. 2-10). Elsevier.
Bai, X., Ihara, E., Otsuka, Y., Tsuruta, S., Hirano, K., Tanaka, Y., Ogino, H., Hirano, M., Chinen, T., Akiho, H., Nakamura, K., Oda, Y., & Ogawa, Y. (2019). Involvement of different receptor subtypes in prostaglandin E2-induced contraction and relaxation in the lower esophageal sphincter and esophageal body. European journal of pharmacology, 857, 172405. https://doi.org/10.1016/j.ejphar.2019.172405
Umetsu, Y., Tenno, T., Goda, N., Shirakawa, M., Ikegami, T., & Hiroaki, H. (2011). Structural difference of vasoactive intestinal peptide in two distinct membrane-mimicking environments. Biochimica et biophysica acta, 1814(5), 724-730. https://doi.org/10.1016/j.bbapap.2011.03.009
Tobias, A., & Sadiq, N. M. (2022). Physiology, Gastrointestinal Nervous Control. In StatPearls. StatPearls Publishing.
Iwasaki, M., Akiba, Y., & Kaunitz, J. D. (2019). Recent advances in vasoactive intestinal peptide physiology and pathophysiology: focus on the gastrointestinal system. F1000Research, 8, F1000 Faculty Rev-1629. https://doi.org/10.12688/f1000research.18039.1
Allan, V. J. (2000) Basic immunofluorescence. Protein localization by fluorescence microscopy: a practical approach (pp. 1-26). Oxford University Press.
Tsukada, T., Horovitch, S. J., Montminy, M. R., Mandel, G., & Goodman, R. H. (1985). Structure of the human vasoactive intestinal polypeptide gene. DNA (Mary Ann Liebert, Inc.), 4(4), 293-300. https://doi.org/10.1089/dna.1985.4.293
Said, S. I., & Rosenberg, R. N. (1976). Vasoactive intestinal polypeptide: abundant immunoreactivity in neural cell lines and normal nervous tissue. Science (New York, N.Y.), 192(4242), 907-908. https://doi.org/10.1126/science.1273576
Delgado, M., Pozo, D., & Ganea, D. (2004). The significance of vasoactive intestinal peptide in immunomodulation. Pharmacological reviews, 56(2), 249-290. https://doi.org/10.1124/pr.56.2.7
Haidarzhi, Ye. I. (2023). Dynamics of prostaglandin E2 in the surgical treatment of gastroesophageal reflux disease. Pathologia, 20(1), 58-62. https://doi.org/10.14739/2310-1237.2023.1.273146
Martinez, C., Delgado, M., Abad, C., Gomariz, R. P., Ganea, D., & Leceta, J. (1999). Regulation of VIP production and secretion by murine lymphocytes. Journal of neuroimmunology, 93(1-2), 126-138. https://doi.org/10.1016/s0165-5728(98)00216-1
Downloads
Published
How to Cite
Issue
Section
License
Authors who publish with this journal agree to the following terms:
- Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access)
